secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARDELYX, INC. (ARDX)
CIK:        0001437402
Form:       8-K
Filed at:   2022-12-29T23:59:59+00:00
Accession:  0001628280-22-032662
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Ardelyx receives FDA appeal grant for XPHOZAH; plans NDA resubmission in H1 2023
--------------------------------------------------------------------------------

- On Dec 27, 2022, FDA OND granted appeal of July 2021 CRL for XPHOZAH (tenapanor) after Nov 16 CRDAC favorable vote.
- OND directs Division of Cardiology and Nephrology to work with Ardelyx on label development for hyperphosphatemia insufficiently managed on binder therapy.
- Company expects to resubmit NDA in H1 2023; review classification (Class 1: 2 months, Class 2: 6 months) to be determined post-resubmission.
- This reverses prior complete response letter and represents a major regulatory milestone for Ardelyx's only late-stage candidate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1437402/000162828022032662/0001628280-22-032662-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1437402/000162828022032662/ardx-20221227.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-032662

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer